TherOx announces key data presentations and company-sponsored events for SuperSaturated Oxygen (SSO2) Therapy at the upcoming Transcatheter Cardiovascular Therapeutics (TCT) annual scientific symposium Sept. 25-29 at the Moscone Center in San Francisco.
THEROX ANNOUNCES KEY SUPERSATURATED OXYGEN THERAPY PRESENTATIONS AT TCT 2019
IRVINE, Calif., Sept. 18, 2019 – TherOx, a ZOLL® Medical company, announces key data presentations and company-sponsored events for SuperSaturated Oxygen (SSO2) Therapy at the upcoming Transcatheter Cardiovascular Therapeutics (TCT) annual scientific symposium Sept. 25-29 at the Moscone Center in San Francisco.
Presentations include an overview and case study of SSO2 Therapy – the first and only FDA-approved new heart attack treatment beyond PCI to reduce infarct size – and updated results of the IC-HOT (Evaluation of Intracoronary Hyperoxemic Oxygen Therapy) study conducted to support FDA approval, granted in April 2019. The following presentations will take place on Thursday, Sept. 26:
- “One Year Outcomes of Supersaturated Oxygen Therapy in Acute Anterior Myocardial Infarction: The IC HOT Study” will be shared by Dr. Shmuel Chen of NY Presbyterian Hospital – Columbia Presbyterian Center New York at 12:40 p.m. in the Poster Hall.
- “SSO2 Therapy: STEMI Case Studies” will be presented by Dr. Amir Lotfi of Baystate Medical Center, Tufts University School of Medicine at 2 p.m. in Hall D.
- “Infarct Size Reduction: From the First FDA Approved Therapy SSO2 to Novel Approach” will be presented by Dr. Gregg W. Stone of Columbia University Medical Center in New York at 4:35 p.m. in Room 151/153.
In addition, TherOx is sponsoring a breakfast symposium on Sept. 26 at 6:30 a.m. in Room 215 of Moscone South. “SuperSaturated Oxygen in STEMI to Reduce Infarct Size – A New FDA Approved Therapy” will be presented by Dr. Stone, Dr. Suzanne de Waha-Thiele of University Heart Center Luebeck in Germany, Dr. Magnus Ohman of Duke Medicine in North Carolina, Dr. Richard Spears of Beaumont Heart & Vascular Center in Michigan, and Dr. Richard A. Schatz of Scripps Health in San Diego.
TherOx will be exhibiting in booth #1852.
About SSO2 Therapy
SSO2 Therapy is based on the known benefits of hyperbaric oxygen treatment in improving the body’s ability to heal. SSO2 Therapy infuses superoxygenated blood to improve microvascular flow and has been shown in controlled clinical studies to safely reduce infarct size in qualifying anterior AMI patients. Immediately after the coronary artery has been opened by PCI, SSO2 Therapy delivers a one-time, 60-minute infusion of the patient’s superoxygenated blood to the left main coronary artery through a small catheter. The effect of the superoxygenated infusion is to reverse ischemia-induced capillary edema and to increase blood flow to surrounding tissue,(1)(2) thereby decreasing infarct size.(3) SSO2 Therapy is aligned with current guidelines for interventional cardiology procedures.
SSO2 Therapy is indicated for the preparation and delivery of supersaturated oxygen to targeted ischemic regions perfused by the patient’s left anterior descending coronary artery immediately following revascularization by means of percutaneous coronary intervention (PCI) with stenting that has been completed within six hours after the onset of anterior acute myocardial infarction (AMI) symptoms caused by a left anterior descending artery infarct lesion.
For more information about SSO2 Therapy and TherOx, visit www.therox.com.
About ZOLL Medical Corporation
ZOLL Medical Corporation, an Asahi Kasei Group company, develops and markets medical devices and software solutions that help advance emergency care and save lives, while increasing clinical and operational efficiencies. With products for defibrillation and monitoring, circulation and CPR feedback, data management, fluid resuscitation, therapeutic temperature management, and ventilation, ZOLL provides a comprehensive set of technologies that help clinicians, EMS and fire professionals, and lay rescuers treat victims needing resuscitation and acute critical care. For more information, visit www.zoll.com.
About Asahi Kasei
The Asahi Kasei Group is a diversified group of companies led by holding company Asahi Kasei Corporation, with operations in the material, homes, and health care business sectors. Its health care operations include devices and systems for acute critical care, dialysis, therapeutic apheresis, transfusion, and manufacture of biotherapeutics, as well as pharmaceuticals and diagnostic reagents. With more than 30,000 employees around the world, the Asahi Kasei Group serves customers in more than 100 countries. For more information, visit www.asahi-kasei.co.jp/
- Spears JR, et al. Aqueous Oxygen Attenuation of Reperfusion Microvascular Ischemia in a Canine Model of Myocardial Infarction. ASAIO Jour. 2003 Nov-Dec;49(6):716-20.
- Bartorelli A, et al. Hyperoxemic Perfusion for Treatment of Reperfusion Microvascular Ischemia in Patients with Myocardial Infarction. Am Jour of Cardio Drugs. 2003. 3(4); 253-263.
- Stone GW, Martin JL, de Boer MJ, et al. Effect of Supersaturated Oxygen Delivery on Infarct Size after Percutaneous Coronary Intervention in Acute Myocardial Infarction. Circ Cardiovasc Intervent 2009;2:366-75
CONTACT: Joni Ramirez, Merryman Communications, joni@merrymancommunications.
